Snell & Wilmer (JD Supra China)

China has the world’s second largest economy. Few businesses would turn away from its practically limitless potential, or so it would seem. But many do, avoiding this market altogether, or more commonly merely tiptoeing into the market with an effort that pales in comparison to other regions, such as Europe, the Americas and other Pacific-Rim countries. Intellectual Property is often cited as the

With more than 1.4 billion consumers, China is an integral participant in the global marketplace and has made great strides in modernizing its economy and taking a strong position in the international economic and political community. However, China has been known for manufacturing the technology developed in other countries, it is quickly developing the resources — human and capital — to take...

China has been home to more than 1,800 clinical trials of pharmaceuticals intended for U.S. use. With its large and growing English-speaking population, the country, along with India, is a foreign clinical trial destination poised to “eclipse all the others,” according to recent coverage in Vanity Fair.[1] The country is at the forefront of a larger trend in moving clinical trials abroad—in 2008,

Many businesses in the Southwest have growth strategies that feature opportunities in China. Since 2001, China has skyrocketed from being Arizona’s 17th highest export destination to its third highest — currently behind only Mexico and Canada. In the past decade, exports from Arizona to China have grown at an astounding annual average of nearly 37 percent. Similar narratives apply to...

The Foreign Corrupt Practices Act, 15 U.S.C. §§ 78dd-1, et seq. (FCPA), makes it illegal to make payments to foreign government officials to assist in obtaining or retaining business. The FCPA specifically prohibits a person or company from making a bribe to a foreign official to influence that official to violate his or her lawful duties or to secure an improper advantage in obtaining or...